louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01371539: Clinical Comparison of Two Multifocal Contact Lenses Made of Silicone Hydrogel Materials
Official title: Clinical Comparison of Two Multifocal Contact Lenses Made of Silicone Hydrogel Materials
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myopia
Presbyopia
Keywords: Myopia
Presbyopia
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2011-06-13
Enrollment: 109
Sex: ALL
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to compare visual performance measures between two multifocal contact lenses on presbyopic wearers.


Eligibility criteria: Inclusion Criteria:

* At least 35 years of age.
* Spectacle add of +0.50 to +2.50 diopters (inclusive).
* Currently wearing soft contact lenses at least 5 days per week and at least 8 hours per day.
* Able to be fit in both eyes with soft multifocal lenses in available powers.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Eye injury or surgery within 12 weeks of enrollment in trial.
* Currently enrolled in any clinical trial.
* Astigmatism of 1.00 diopter or more.
* Currently wearing excluded brands of multifocal lenses, as specified by protocol.
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Corrected Distance Binocular Visual Measurement in Normal Illumination Reported as Binocular Distance Visual Acuity
timeFrame: 1 week
measure: Corrected Near Binocular Visual Measurement in Normal Illumination Reported as Binocular Near Visual Acuity
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Alcon Research
name: Stacie Cummings, O.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02258139: Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact Lens
Official title: The Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact Lens
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Corneal Deformity
Lead sponsor: Bausch & Lomb Incorporated
Sponsor class: INDUSTRY
First posted: 2014-10-07
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This will be a randomized non-dispensing study comparing the overnight corneal swelling of an eye while wearing no contact lens to the Ultra contract lens.


Eligibility criteria: Inclusion Criteria:

* Be between 18 and 40 years of age (inclusive)
* Not a current contact lens wearer (have not worn extended wear, and not worn in lenses in 6 months)
* Able to read, comprehend and sign an informed consent
* Willing to comply with the wear and study visit schedule
* Monocular best-corrected distance visual acuity \>/-20/25 in each eye

Exclusion Criteria:

* Any active corneal infection, disease, injury, inflammation, past surgery, or ocular abnormality which may interfere with contact lens wear
* Systemic or ocular allergies, which might interfere with contact lens wear
* Systemic disease or condition, which might interfere with contact lens wear
* Use of prescription sleep aids or alcohol within 24 hours of study appointment
* Inability to wear contact lenses
* Under 18 years of age

Primary outcomes:
measure: Percent Change in Central Corneal Thickness
timeFrame: 8 hours
Secondary outcomes:
measure: Time to Restore Central Corneal Thickness
timeFrame: 48 hours
Other outcomes:
Locations:
city: Bloomington
country: United States
facility: Indiana University
state: Indiana
Study officials:
affiliation: Bausch & Lomb Incorporated
name: Robert Steffen, OD, MS
role: STUDY_DIRECTOR
References:
Clinical trial NCT01657786: Association of 5-HT3 Receptor Gene Polymorphism With the Efficiency of Ondansetron for Postoperative Nausea and Vomiting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Post Operative Nausea and Vomiting
Keywords: ondanstron
gene polymorphism
postoperative nausea and vomiting
laparoscopic surgery under general anesthesia
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2012-08-06
Enrollment: 198
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Postoperative nausea and vomiting (PONV) is a common and distressing complication in patients undergoing general anesthesia. However, although 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists have significantly reduced PONV, it is reported that over 35% of patients treated with ondansetron experience PONV. Though the cause of failure in ondansetron treatment is not clear, the investigators assumed that polymorphism in the 5-HT3 receptor gene would contribute to such inter-individual variation. In this study, the investigators examine whether the polymorphisms of 5-HT3 receptor gene affect the efficacy of ondansetron to prevent PONV in patients undergoing general anesthesia for laparoscopic surgery.


Eligibility criteria: Inclusion Criteria:

* Adult patients (20-90 years of age) scheduled for undergoing laparoscopic surgery undergoing general anesthesia

Exclusion Criteria:

* Patients with previous history of drug allergy,
* administration of antiemetic drugs within 24 hours,
* nausea/vomiting within 24 hours and liver or kidney disease

Primary outcomes:
measure: The relationship between the incidence of PONV after ondansetron administration and genotypes in 5-HT3 receptor gene polymorphisms ((5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG)
timeFrame: at first 2 h and 2-24 h after surgery.
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Associate Professor Department of Anesthesiology and Pain Medicine
Study officials:
References:
Clinical trial NCT06716086: A Novel Shape Memory Alloy-Based Orthosis for Proximal Interphalangeal Joint Stiffness
Official title: A Novel Shape Memory Alloy-Based Orthosis for Proximal Interphalangeal Joint Stiffness
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Finger Proximal Interphalangeal Joint Contracture
Keywords: shape memory alloy
finger stiffness
joint contracture
joint range of motion
hand injury
Lead sponsor: National Cheng-Kung University Hospital
Sponsor class: OTHER
First posted: 2024-12-04
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to evaluate the applicability, effectiveness, and usability of a shape memory alloy-based orthosis for patients with finger proximal interphalangeal joint stiffness. This cutting-edge design incorporates shape memory alloy into the device for improving proximal interphalangeal joint stiffness and, secondarily, enhancing the ability to perform activities.

Half of the participants will be assigned to experimental group, receiving a shape memory alloy-based orthosis for home program. The other half will be assigned to control group, receiving a conventional stretching program. Three evaluations, examining range of motion and hand functional performance, will be conducted before intervention, 4 weeks and 8 weeks after baseline by the researchers.


Eligibility criteria: Inclusion Criteria:

* 18-79 years old
* Exhibit limitations in passive range of motion of the proximal interphalangeal joint, with extension less than 0 degrees or flexion less than 90 degrees.
* Beyond the acute phase of the hand condition, and it has been more than 8 weeks post-surgery (or post-injury).

Exclusion Criteria:

* Concurrently use other types of splints for PIP joint stiffness.
* Present with abnormal muscle tone, paralysis, or rigidity associated with central or peripheral nervous system dysfunction.
* Suffer from complex regional pain syndrome or progressive degenerative disease affecting finger joints, such as rheumatoid arthritis.
* Have an active infection or arthritis in their fingers.
* Unable to follow instructions.

Primary outcomes:
measure: Range Of Motion
timeFrame: Baseline, 4 weeks after baseline, and 8 weeks after baseline
Secondary outcomes:
measure: Minnesota Manual Dexterity Test
timeFrame: Baseline, 4 weeks after baseline, and 8 weeks after baseline
measure: Purdue Pegboard Test
timeFrame: Baseline, 4 weeks after baseline, and 8 weeks after baseline
measure: Motion Capture and Analysis System
timeFrame: Baseline, 4 weeks after baseline, and 8 weeks after baseline
measure: The Disability of the Arm, Shoulder and Hand Questionnaire, Taiwan version
timeFrame: Baseline, 4 weeks after baseline, and 8 weeks after baseline
measure: System Usability Scale
timeFrame: 8 weeks after baseline
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: National Cheng-Kung University Hospital
Study officials:
References:
Clinical trial NCT06119386: Quantum Molecular Resonance Electrotherapy in Severe Dry Eye Disease
Official title: Quantum Molecular Resonance Electrotherapy in Severe Dry Eye Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dry Eye
Keywords: Cornea
Dry Eye
Lead sponsor: Centro Oculistico Borroni
Sponsor class: OTHER
First posted: 2023-11-07
Enrollment: 81
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of Quantum Molecular Resonance (QMR) treatment in patients with severe dry eye disease (DED), as well as its effects on aqueous-deficient (ADDE), evaporative (EDE) and mixed (MDE) dry eye.

Detailed description: To evaluate the efficacy and safety of Quantum Molecular Resonance (QMR) treatment in patients with severe dry eye disease (DED), as well as its effects on aqueous-deficient (ADDE), evaporative (EDE) and mixed (MDE) dry eye.

In this prospective, interventional study, 81 patients will be randomly allocated to received 4 treatment sessions of QMR at one-week intervals (Rexon-Eye ® , Resono Ophthalmic, Trieste, Italy) (QRM group) or tear substitute 4 times daily, containing 0.15% sodium hyaluronate and 3% trehalose (Thealoz Duo ® , Thea Pharma, France) (SH-TH group).

Outcomes measures will include ocular surface disease index (OSDI) questionnaire, tear meniscus height (TMH), tear breakup time (TBUT), non-invasive breakup time (NIBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), tear film osmolarity (OSM) and meibomian gland dysfunction (MGD) grade at baseline, 1-month and 3-months follow-up.

Eligibility criteria: Inclusion criteria:

-\> 18 years old with a self-reported history of DED

* OSDI score ≥ 33 points
* TBUT less than 10 seconds.

Exclusion criteria:

* skin pathologies that prevent QRM treatment
* corneal infection and corneal dystrophies
* active ocular allergies
* intraocular surgery or laser ocular surgery

Primary outcomes:
measure: Ocular surface evaluation
timeFrame: 3 month
Secondary outcomes:
Other outcomes:
Locations:
city: Gallarate
country: Italy
facility: Centro Oculistico Borroni
state: VA
Study officials:
References:
citation: Foo VHX, Liu YC, Tho B, Tong L. Quantum molecular resonance electrotherapy (Rexon-Eye) for recalcitrant dry eye in an Asian population. Front Med (Lausanne). 2023 Sep 12;10:1209886. doi: 10.3389/fmed.2023.1209886. eCollection 2023.
Clinical trial NCT03018639: Impact of Therapist Change on Dropout in a Naturalistic Sample of Inpatients With Borderline Pathology Receiving DBT
Official title: Impact of Therapist Change After Initial Contact and Traumatic Burden on Dropout in a Naturalistic Sample of Inpatients With Borderline Pathology Receiving Dialectical Behavior Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Borderline Personality Disorder
PostTraumatic Stress Disorder
Psychotherapy
Dropout
Lead sponsor: Evangelisches Krankenhaus Bielefeld gGmbH
Sponsor class: OTHER
First posted: 2017-01-12
Enrollment: 89
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: For this study, all patients aged from 18 to 65, discharged from our personality disorder inpatient unit between December 2012 and August 2016, and fulfilling three or more criteria for BPD as defined by DSM-IV (Borderline Personality characteristics; BPC) were considered (n = 89).

Brief summary: Participants with Borderline pathology (≥ 3 DSM-IV-criteria) receiving an inpatient Dialectical Behavior Therapy (DBT) program completed a quality assurance questionnaire set assessing demographic information and pretreatment psychopathology during the days of their inpatient stay. Beyond that, changes of therapists were documented.


Eligibility criteria: Inclusion Criteria:

* three or more criteria for BPD as defined by DSM-IV (Borderline Personality characteristics; BPC)

Exclusion Criteria:

* inability to contract and consent,
* other severe mental disorders (bipolar disorder, acute psychosis),
* current alcohol,
* illicit or not prescribed drug use,
* simultaneous participation in other treatment studies,
* pregnancy or breastfeeding,
* an inability to negotiate a non-suicide agreement,
* ongoing traumatic contact with the perpetrator, and
* a Body Mass Index \< 16.5.

Primary outcomes:
measure: Dropout
timeFrame: 10 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Bielefeld
country: Germany
facility: Research Department
Study officials:
affiliation: Research Department, Ev. Krankenhaus Bielefeld
name: Martin Driessen
role: STUDY_DIRECTOR
References:
citation: Steuwe C, Berg M, Driessen M, Beblo T. Impact of therapist change after initial contact and traumatic burden on dropout in a naturalistic sample of inpatients with borderline pathology receiving dialectical behavior therapy. Borderline Personal Disord Emot Dysregul. 2017 Jun 22;4:14. doi: 10.1186/s40479-017-0067-3. eCollection 2017.
Clinical trial NCT01153386: Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine
Official title: An Evaluation of the Pharmacokinetic Linearity and Comparative Bioavailability of a Single Oral Dose of 0.5 mg, 1 mg and 2.5 mg UT-15C (Treprostinil Diethanolamine) SR Tablets in Healthy Volunteers in the Fed State
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pulmonary Arterial Hypertension
Keywords: Pulmonary arterial hypertension
Treprostinil
Pharmacokinetics
Lead sponsor: United Therapeutics
Sponsor class: INDUSTRY
First posted: 2010-06-30
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study will compare the bioavailability and pharmacokinetics of the 0.5 mg, 1 mg and 2.5 mg treprostinil diethanolamine tablet strengths in healthy volunteers.

Detailed description: This study was designed to assess the pharmacokinetic linearity and comparative bioavailability of UT-15C SR (treprostinil diethanolamine) following the administration of a single tablet containing 0.5 mg, 1 mg and 2.5 mg UT-15C in healthy volunteers.

Eligibility criteria: Inclusion Criteria:

* Subject is healthy and between the ages of 18 and 55 years
* Female subjects must weigh between 55 and 100 kg, inclusive, with a BMI between 19.0-29.9 kg/m2, inclusive at Screening. Male subjects must weigh between 55 and 120 kg, inclusive, with a BMI between 19.0-32.0 kg/m2, inclusive at Screening.
* Subject has a medical history, physical examination, vital signs, ECG and clinical laboratory results within normal limits or considered not clinically significant by the Investigator at Screening.

Exclusion Criteria:

* Subject has any clinically relevant abnormality identified during the screening physical examination, 12-lead ECG, or laboratory examinations.
* Subject has a history of anaphylaxis, a documented hypersensitivity reaction, or a clinically significant idiosyncratic reaction to any drug.
* Subject has a clinically significant history of neurological, cardiovascular, respiratory, endocrine, hematological, hepatic, renal, gastrointestinal, genitourinary, pulmonary and/or musculoskeletal disease; glaucoma; a psychiatric disorder or any other chronic disease, whether controlled by medication or not.

Primary outcomes:
measure: Treprostinil pharmacokinetics
timeFrame: 36 hours
Secondary outcomes:
measure: Clinical laboratories
timeFrame: Study Days 0, 7, 14 and 16.
measure: Adverse event monitoring
timeFrame: From the first dose of treprostinil diethanolamine through the end of the study (Study Day 16)
Other outcomes:
Locations:
city: Austin
country: United States
facility: PPD Development
state: Texas
Study officials:
affiliation: PPD Development, LP
name: Thomas L Hunt, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02355639: A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin
Official title: A Single-Centre, Explorative, Randomised, Investigator-Blinded, Negative-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess Steroid Induced Skin Atrophy on Healthy Skin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Skin and Connective Tissue Diseases
Lead sponsor: LEO Pharma
Sponsor class: INDUSTRY
First posted: 2015-02-04
Enrollment: 16
Sex: MALE
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to assess steroid induced skin atrophy by sonography.


Eligibility criteria: Inclusion Criteria:

1. Healthy male volunteers, 25 to 40 years old inclusive.
2. Healthy skin on volar arms with a hairless area sufficient for measurements

Exclusion Criteria:

1. Clinical skin atrophy, telangiectasia or striae on volar arms.
2. Presence of any skin condition or colouration that would interfere with test sites or the response or assessment.
3. Fitzpatrick skin type IV - VI.
4. History or current evidence of infection, eczema or other relevant skin disease.

Primary outcomes:
measure: Change in skin thickness from baseline to end of treatment
timeFrame: 4 weeks
Secondary outcomes:
measure: Relation of clinical features (skin transparency and telangiectasia) to the steroid induced skin atrophy after end of treatment
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité - Universitaetsmedizin Berlin, Department of Dermatology and Allergy
Study officials:
References:
Clinical trial NCT03013439: Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)
Official title: Phase I Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®) Administered as Single Bolus Injections or Infusions in Japanese Subjects With Iron Deficiency Anemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Anemia
Deficiency Diseases
Anemia, Iron Deficiency
Hematologic Disease
Iron Metabolism Disorders
Lead sponsor: Pharmacosmos A/S
Sponsor class: INDUSTRY
First posted: 2017-01-06
Enrollment: 24
Sex: ALL
Minimum age (years): 20
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The trial is an open-label, 4 cohorts, sequential, dose-escalating, single dose trial.

Detailed description: IDA is highly prevalent in subjects with cancer and gastrointestinal diseases such as inflammatory bowel diseases, menstruating or pregnant women, and subjects who have undergone bariatric procedure. IDA can have a substantial medical and quality of life (QoL) burden on the subjects, and treatment of these subjects includes controlling the bleeding and replenishing lost iron.

Eligibility criteria: Inclusion Criteria:

1. Japanese man or woman ≥ 20 years, \< 65 years of age
2. Hb of ≥ 9.0 g/dL, \< 12.0 g/dL for women and \< 13.0 g/dL for men
3. Serum ferritin \< 25 ng/mL
4. TIBC ≥ 360 μg/dL
5. Body weight ≥ 50 kg
6. Willingness to participate and signing the informed consent form

Exclusion criteria include:

1. Anemia caused by conditions other than iron deficiency
2. Cancer
3. IV or oral iron treatment, or blood transfusion 4 weeks prior to screening
4. Erythropoiesis stimulating agent (ESA) treatment prior to screening
5. Imminent expectation of blood transfusion on part of treating physician
6. Iron overload or disturbances (e.g. hemochromatosis and hemo-siderosis)
7. Known hypersensitivity reaction to iv iron preparations
8. Decompensated liver cirrhosis or active hepatitis
9. Active acute or chronic infections
10. Pregnant or nursing women.
11. Planned elective surgery during the trial

Primary outcomes:
measure: Proportion of adverse events
timeFrame: 1 week
Secondary outcomes:
measure: Maximum plasma drug concentration [Cmax]
timeFrame: 1 week
measure: Area Under the Curve [AUC]
timeFrame: 1 week
measure: Time to reach one-half of the maximum drug concentration [T1/2]
timeFrame: 1 week
measure: Time to reach maximum drug concentration [Tmax]
timeFrame: 1week
measure: Change in concentration of hemoglobin (g/dL)
timeFrame: 1 week
measure: Change in concentration of serum ferritin (ng/mL)
timeFrame: 1 week
measure: Change in concentration of total iron binding capacity (μg/dL )
timeFrame: 1 week
measure: Change in concentrations of transferrin saturation (%)
timeFrame: 1 week
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Ikebukuro
Study officials:
References:
Clinical trial NCT01851239: Venous Thromboembolism Prophylaxis in Medical and Surgical ICUs in a Single University Hospital
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Venous Thromboembolism
Keywords: Venous Thromboembolism Prophylaxis
ICU
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2013-05-10
Enrollment: 1000
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: ICU admitted patients who are indicated for VTE prophylaxis.

Brief summary: Venous thromboembolism(VTE) is the third most common cardiovascular complication among hospitalized patients, and can even cause death. VTE often occurs in intensive care patients and there had been many efforts to prevent such complication. The American College of Chest Physicians (ACCP) had published evidence-based clinical practice guideline for VTE prophylaxis.

This study focuses on how VTE prophylaxis is being performed in both medical and surgical ICUs in a single University hospital, and sees the differences in such prophylactic patterns.


Eligibility criteria: Inclusion Criteria:

* ICU admitted patients

Exclusion Criteria:

* patients under 20 years old

Primary outcomes:
measure: number of patients prescribed with any measures of VTE prophylaxis in ICU
timeFrame: at the time of ICU admission an expected average of 5 months (When VTE prophylaxis for each patient is being ordered)
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University College of Medicine
Study officials:
References: